Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CNS Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNSP
Nasdaq
8731
https://cnspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CNS Pharmaceuticals Inc
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
- Apr 1st, 2024 9:00 pm
CNS Pharmaceuticals to Present at Two Investor Conferences in April
- Apr 1st, 2024 1:05 pm
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
- Jan 30th, 2024 2:00 am
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
- Jan 18th, 2024 1:45 pm
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
- Jan 17th, 2024 1:45 pm
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
- Dec 18th, 2023 1:35 pm
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
- Dec 6th, 2023 2:00 pm
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
- Nov 22nd, 2023 2:05 pm
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
- Nov 16th, 2023 3:00 pm
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
- Nov 15th, 2023 1:00 pm
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
- Oct 19th, 2023 1:05 pm
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
- Oct 16th, 2023 1:00 pm
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
- Oct 11th, 2023 12:45 pm
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
- Sep 7th, 2023 12:45 pm
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:45 pm
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
- Aug 14th, 2023 12:35 pm
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
- Aug 14th, 2023 11:35 am
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
- Aug 3rd, 2023 12:15 pm
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
- Aug 3rd, 2023 12:00 pm
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
- Jul 27th, 2023 1:05 pm
Scroll